Remove Medical Remove Negotiation Remove Trading
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

Despite market speculation around potential sales of publicly traded biotech firms fueled by shifting regulatory environments, capital constraints and strategic realignments relatively few large transactions actually took place. Similarly, Novo Holdings $16.5

M&A 64
article thumbnail

How Private Equity uses ‘Roll-up’ Strategies to Drive Investment Returns

OfficeHours

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) More specifically, this might entail negotiating transaction features such as earn-outs, deferred consideration, or seller financing, just to name a few.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Private Equity’s Increasing Consolidation of Oncology Practices 

Focus Investment Banking

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. In addition to negotiated payments, providers can earn incentives for providing high-quality, efficient care. Founded in 2007, publicly-traded TOI provides care to about 1.8

article thumbnail

What is an Original Equipment Manufacturer (OEM)?

Peak Frameworks

Medical Devices In the medical device industry, OEMs contribute to the production of crucial equipment and tools. Medtronic , a leading medical device manufacturer, partners with OEMs like Integer Holdings for producing components such as batteries and electronic systems.

article thumbnail

Top 5 sectors attracting venture capital finance

Growth Business

By Tim Bird on Growth Business - Your gateway to entrepreneurial success It was a buoyant 2018 for venture capital investment into UK and European companies – a trend which defied broader concerns about international trade tensions, economic growth prospects and, of course, Brexit. This is not just a legal necessity.

Finance 52
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40
article thumbnail

Cooley’s 2019 Tech M&A Year in Review

Cooley M&A

Federal Trade Commission (FTC) are particularly focused on acquisitions of “nascent technologies” by incumbent high-tech platforms. Thereafter, plaintiffs’ counsel often demands a “mootness fee” (for the alleged benefit conferred by the supplemental disclosures), over which the parties can negotiate or litigate, if necessary.

M&A 40